GRAL

In the past six months, GRAIL's stock has experienced volatility influenced by clinical trial results, regulatory progress, and corporate announcements. In February 2026, the NHS-Galleri trial results led to a stock price drop, despite highlighting a reduction in Stage IV cancer diagnoses. In March 2026, shares increased after an analyst upgrade and the announcement of a new CEO. In April 2026, the stock saw fluctuations due to upcoming presentations, the CEO transition, the FDA PMA submission for Galleri, and its integration into the Epic Electronic Health Record platform. In May 2026, GRAIL reported strong first-quarter financial results and the FDA accepted its Premarket Approval application for the Galleri test.